The Department of Pancreaticobiliary Surgery, a key department of Sun Yat-sen University Cancer Center, has been focusing on the surgical and comprehensive treatment of various kinds of tumors of the pancreas and biliary tract for decades. It was formerly known as the Department of Hepatobiliary Pancreatic Surgery together with the current Department of Liver Surgery, which was founded in 1998. With the development of subspecialty in our Cancer Center, the Department of Pancreaticobiliary Surgery was established in 2019. Currently, there are 10 doctors and 44 beds in our department. A variety of complex operations concerning the pancreas and biliary tract have been carried out in the department, which include pancreaticoduodenectomy (with or without pylorus-preserving), distal pancreatectomy, hepatopancreatoduodenectomy (HPD), total pancreatectomy, distal pancreatectomy with celiac artery resection (Appleby procedure), duodenum-preserving pancreatic head resection (Beger procedure), radical surgery for Bismuth type III/IV hilar cholangiocellular carcinoma, and basin-shaped hepaticojejunostomy, etc.
In recent years, minimally invasive surgery (including robotic/laparoscopic assisted surgery) has been widely carried out in our department. In addition to surgery, local ablation treatment is carried out. IRE (irreversible electroporation) was introduced into the department in 2015, which was the earliest in Mainland China, and the department was the first "International IRE Training Center" in Mainland China. The first IRE treatment guidelines for pancreatic cancer in China were drafted by our department, with hundreds of patients with locally advanced pancreatic cancer having benefited from IRE treatment. Our experience and achievements in IRE treatment have been selected for oral presentation at the International Oncology Forum and Asian Conference on Tumor ablation. The department also constituted one of the earliest multidisciplinary diagnosis and treatment teams for tumors of the pancreas and biliary tract in China, which included experts and doctors specialized in various fields including surgeons, chemotherapy physicians, radiotherapists, endoscopists, pathologists, radiologists, nutritionists, and interventional doctors. We work together to make sure that each patient’s treatment plan can be well managed based on the principle of individualization. Several clinical trials conducted in the department are in progress on the comprehensive treatment of biliary and pancreatic tumors, including a study on neoadjuvant chemoradiation therapy for BRPC.
In addition to clinical work, the department conducts extensive scientific research. The department has its own biobank, laboratory for basic science, database, and medical transformation laboratory. We have established a long-term and stable cooperative relationship with some other academic institutes such as the University of Michigan. Our department has obtained many projects including the National Key Research and Development Program, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong Province. More than 100 scientific research papers have been published in peer-reviewed journals, and many academic achievements published in internationally renowned journals such as Cell Research, the J Hepatol, Hepatology, PLoS Genetics, Oncoimmunology, and Clin Cancer Res, etc.
The Director of the Department of Pancreaticobiliary Surgery is Professor Shengping Li, a Chief Expert in our Cancer Center, who is a well-known specialist in the field of pancreatic cancer and biliary tract cancer. Prof. Li serves as the chairman of several academic organizations, such as the Society of Pancreatic Cancer as well as the Society of Biliary Tract Cancer of Guangdong Provincial Anti-cancer Association, and the Society of Cancer Prevention and Treatment of Guangdong Health Management Association. He also served as the committee member of the Pancreatic Surgery Group of the Chinese Medical Association. As the chairman of "International IRE Training Center", Prof. Li organized a number of academic conferences to promote the implementation of IRE, which contributed to the popularization of IRE and benefited many patients with locally advanced pancreatic cancer.
Relying on the platform of the State Key Laboratory of Oncology in South China and Sun Yat-sen University Cancer Center, all staff of the Department of Pancreaticobiliary Surgery are dedicated to providing patients with the most effective and comprehensive treatments possible. We will continue to make unremitting efforts to improve the survival and quality of life of the patients with pancreaticobiliary tumors.
Shengping Li, MD, Ph.D
Director of Department of Pancreaticobiliary Surgery
Xiaojun Lin, MD
Xiang-Ming Lao, MD. Ph.D
Bokang Cui, MD, Ph.D
Jun Wang, MD, Ph.D
Yize Mao, MD, Ph.D
Chaobin He, MD, Ph.D
Xin Huang, MD, Ph.D
Ran Wei, MD, Ph.D
Jianzhong Cao, MD, Ph.D
Updated August 2020